Tag: LimFlow
End-stage CLTI: Deep-vein arterialization procedure demonstrates amputation-free survival rate of 66%...
Six-month results from the PROMISE II trial of the LimFlow deep-vein arterialization system showed an overall amputation-free survival of 66%—“well above” the primary endpoint...
Treating PAD: ‘Run, don’t walk, to sign up for this incredible...
No matter if you’re a surgeon with a few years—or a few decades—of experience, faculty members of a new, upcoming Society for Vascular Surgery...
PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI...
Enrollment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialization system designed to prevent amputations in so-called "no-option"...
PROMISE I 24-month results ‘validate the benefits of the LimFlow system’
LimFlow has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialization system, confirming “excellent and sustained outcomes” for...
LimFlow system a ‘cost-effective and high-value alternative’ to traditional therapies
Percutaneous deep vein arterialization (pDVA) with the LimFlow system offers a cost-effective and high-value alternative to traditional therapies or amputation, according to a recent...
One-year results from PROMISE I study of LimFlow system in ‘no-option’...
Twelve-month data from the full patient cohort in the PROMISE I study of the LimFlow percutaneous deep vein arterialization (pDVA) system have been...
Positive two-year data from ALPS registry of LimFlow system published
LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialization (pDVA) system. Results were published...